The Department has no plans currently. The National Institute for Health and Care Excellence is currently developing guidance on Brineura (Cerliponase alfa) for treating neuronal ceroid lipofuscinosis type 2 under the highly specialised technology programme. Further information can be found at the following link:<\/p>
<\/p>
https://www.nice.org.uk/guidance/indevelopment/gid-hst10008<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-02-12", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-02-12T15:49:07.43Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-02-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cerliponase Alfa"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will hold meetings with families of children with ceroid lipofuscinosis type 2 disease on the availability of Brineura on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds North West"}
, "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
], "uin" : "216384"}
, {"_about" : "http://data.parliament.uk/resources/1054661", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1054661/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence will begin reviewing the process and methods for the Highly Specialised Technology Evaluation Programme in 2019/20 with the anticipation that the publication will be achieved by the end of the 2020 calendar year.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-02-12", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-02-12T15:29:54.153Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-02-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what the timeframe is for NICE to publish its review of the Highly Specialised Technologies process.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds North West"}
, "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
], "uin" : "216385"}
, {"_about" : "http://data.parliament.uk/resources/1052416", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1052416/answer", "answerText" : {"_value" : " The Government has no current plans to carry out such an assessment. The National Institute for Health Research is funding research projects that examine drug and alcohol use in young adults and teenagers but none of these are looking at the relationship with sleep disorders.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-02-12", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-02-12T11:32:24.833Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-02-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Sleep: Young People"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Journal of Adolescent Health's editorial article, The Role of Sleep on the Pathway to Substance Abuse in Teens, published in February 2017, if his Department will make an assessment of the implications for his policies of the findings that sleep disorders precede and are predictive of future adolescent substance abuse.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds North West"}
, "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
], "uin" : "215601"}
, {"_about" : "http://data.parliament.uk/resources/1052417", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1052417/answer", "answerText" : {"_value" : " The change to the law to allow access to cannabis-based products for medicinal use does not change existing rules and policies on recreational use and misuse of cannabis. The Government has no plans to legalise cannabis and the penalties for unauthorised supply and possession remain unchanged.<\/p> <\/p> Access to medicinal cannabis is strictly controlled. It must be prescribed by, or under the direction of, a specialist doctor on the Specialist Register of the General Medical Council. The specialist must consider all licensed medicines before prescribing any unlicensed cannabis-based medicine and such a prescription must be in the patient\u2019s best interest, taking into consideration the evidence of benefit and potential for harm to that particular patient.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-02-12", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-02-12T11:31:10.973Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-02-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cannabis: Abuse"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the British Medical Journal's article, Assessment and management of cannabis use disorders in primary care, published on 1 April 2010, if his Department will make an assessment of the implications for his policies of the findings on cannabis use disorder referenced in that article.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds North West"}
, "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
], "uin" : "215602"}
, {"_about" : "http://data.parliament.uk/resources/1052425", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1052425/answer", "answerText" : {"_value" : " The NHS Long Term Plan published in January 2019 sets out the Government\u2019s ambitions to see 55,000 more people surviving cancer for five years in England each year from 2028 and three quarters of all cancers detected at an early stage by 2028. To achieve these targets, we will need to make significant progress on survival across all cancers, including pancreatic cancer.<\/p> <\/p> NHS England will shortly be introducing a Faster Diagnostic Standard of 28 days for all cancer patients which, when taken together with the 62-day referral to treatment standard, will mean that all patients should expect to start their treatment within 34 days of diagnosis. This is a maximum, and trusts should continue to treat patients more quickly particularly where there is a strong clinical need.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2019-02-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-02-07T15:20:39.517Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-02-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pancreatic Cancer"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make it his policy that pancreatic cancer patients receive treatment within 20 days of diagnosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds North West"}
, "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
], "uin" : "215608"}
, {"_about" : "http://data.parliament.uk/resources/1043718", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1043718/answer", "answerText" : {"_value" : " The costs of branded medicines are controlled by the statutory and voluntary schemes for branded medicines. Under those schemes, any price increase needs to be agreed by the Department.<\/p> <\/p> For unbranded generic medicines, the Department encourages competition between suppliers to drive prices down. This means that prices fluctuate because of normal market forces and can go up as well as down. The Department is working with the supply chain to ensure that patients continue to get their medicines and the supply chain for medicines is not interrupted if the United Kingdom leaves the European Union without a deal. In such a scenario it is expected that prices remain stable. There are, however, circumstances that are outside of the control of the Department, for example fluctuations in the exchange rate or an increase in the cost of raw materials that may impact on prices of generic medicines.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"}
}
, "answeringMemberConstituency" : {"_value" : "Wimbledon"}
, "answeringMemberPrinted" : {"_value" : "Stephen Hammond"}
, "dateOfAnswer" : {"_value" : "2019-01-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-23T13:49:23.413Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-01-18", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what contingencies are in place to protect against drug price increases in the event of the UK leaving the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds North West"}
, "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
], "uin" : "210053"}
, {"_about" : "http://data.parliament.uk/resources/1035137", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1035137/answer", "answerText" : {"_value" : " Since 2015 Public Health England has published experimental statistics on breastfeeding prevalence at six to eight weeks. These data can be found at the following link:<\/p> <\/p> https://www.gov.uk/government/collections/breastfeeding-statistics<\/a><\/p> <\/p> These data are based on an interim voluntary data collection by local authorities. Prior to 2015, this data was published by NHS England and is not comparable due to methodological changes.<\/p> <\/p> Breastfeeding prevalence at six to eight weeks data is also available in the Public Health Outcomes Framework. These data can be found at the following link:<\/p> <\/strong><\/p> https://fingertips.phe.org.uk/profile/public-health-outcomes-framework/data#page/11/gid/1000042/pat/6/par/E12000001/ati/102/are/E06000005<\/a><\/p> <\/strong><\/p> There is no comparable data available for earlier years due to methodological changes.<\/p> <\/p> Breastfeeding prevalence at six, 12 and 24 months is not reported nationally.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2019-01-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-09T17:34:59.187Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-01-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Breastfeeding"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what information his Department holds on breastfeeding prevalence at (a) six to eight weeks, (b) six months, (c) 12 months and (d) 24 months in each year since 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
}
, "tablingMemberConstituency" : {"_value" : "Leeds North West"}
, "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
], "uin" : "205404"}
, {"_about" : "http://data.parliament.uk/resources/1035138", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1035138/answer", "answerText" : {"_value" : " Public Health England (PHE) is committed to improving breastfeeding rates across England and has identified breastfeeding as a key priority within our maternity and child health programmes.<\/p> PHE works nationally to support local authorities (LAs) to improve breastfeeding rates. PHE, in partnership with the United Nations International Childrens\u2019 Emergency Fund (UNICEF), published an infant feeding commissioning toolkit to support the commissioning of interventions to improve breastfeeding rates, available at the following link:<\/p> https://www.gov.uk/government/publications/infant-feeding-commissioning-services<\/a><\/p> LAs and their partners are encouraged to provide a comprehensive universal service with access to specialist support when needed. The PHE breastfeeding fingertips profiles allow local areas to see performance against a range of indicators supporting them to plan and review services and local population needs. More information is available at the following link:<\/p>